H.C. Wainwright analyst Swayampakula Ramakanth raised the firm’s price target on Quantum-Si (QSI) to $5.50 from $4 and keeps a Buy rating on the shares. The company hosted an investor day to unveil its new and enhanced protein sequencing technology as well as discuss its go-to-market strategy, the analyst tells investors in a research note. The firm says Quantum-Si’s new sequencing platform “could be a game-changer.” Proteus could help to significantly deepen and broaden market penetration beyond academic institutions to government and pharma sectors, who may be able to utilize the technology for applications, such as translational medicine, drug discovery, and diagnostics, contends H.C. Wainwright.
Invest with Confidence:
- Follow TipRanks' Top Wall Street Analysts to uncover their success rate and average return.
- Join thousands of data-driven investors – Build your Smart Portfolio for personalized insights.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on QSI:
- Quantum-Si and SkyWater Technology expand relationship to develop Proteus
- Quantum-Si price target lowered to $1 from $1.50 at Canaccord
- Quantum-Si Reports Q3 2024 Financial Results
- Quantum-Si says ‘ likely’ will not meet FY24 revenue view of $3.7M-$4.2M
- Quantum-Si reports Q3 EPS (18c), consensus (19c)